Page last updated: 2024-11-12

rrx-001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RRx-001: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	15950826
CHEMBL ID	3526802
SCHEMBL ID	2249018
MeSH ID	M0580411

Synonyms (33)

Synonym
S8405
rrx 001 [who-dd]
radiosensitizer rrx-001
abdnaz
n-(bromoacetyl)-3,3-dinitroazetidine
2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one
rrx-001
unii-7rpw6su9sc
925206-65-1
2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
7rpw6su9sc ,
ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-
HY-16438
CS-5286
SCHEMBL2249018
AC-32908
CHEMBL3526802
rrx 001
1-bromoacetyl-3,3-dinitroazetidine
P15978
AS-53015
DB12060
rrx001
BCP19228
mfcd25976849
CCG-267126
EX-A2006
Q27268765
AKOS037644389
2-bromo-1-(3,3-dinitro-1-azetidinyl)ethanone
SY100127
BR164811
c5h6brn3o5

Research Excerpts

Toxicity

The primary objective was to assess safety, tolerability, and dose-limiting toxic effects of RRx-001. The goal was to determine single-dose pharmacokinetics, and to identify a recommended dose for phase 2 trials.

Excerpt	Reference	Relevance
" The primary objective was to assess safety, tolerability, and dose-limiting toxic effects of RRx-001, to determine single-dose pharmacokinetics, and to identify a recommended dose for phase 2 trials."	( Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Abrouk, NED; Burris, HA; Cabrales, P; Carter, CA; Fanger, GR; Fitch, WL; Infante, JR; Kim, MM; Knox, SJ; Korn, R; Lao, CD; Ning, S; Oronsky, A; Oronsky, B; Peehl, DM; Reid, T; Scicinski, J; Scribner, CL; Stirn, M; Taylor, MJ, 2015)	0.95
" Pain at the injection site, mostly grade 1 and grade 2, was the most common adverse event related to treatment, experienced by 21 (84%) patients."	( Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Abrouk, NED; Burris, HA; Cabrales, P; Carter, CA; Fanger, GR; Fitch, WL; Infante, JR; Kim, MM; Knox, SJ; Korn, R; Lao, CD; Ning, S; Oronsky, A; Oronsky, B; Peehl, DM; Reid, T; Scicinski, J; Scribner, CL; Stirn, M; Taylor, MJ, 2015)	0.73
"RRx-001 is a well-tolerated novel compound without clinically significant toxic effects at the tested doses."	( Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Abrouk, NED; Burris, HA; Cabrales, P; Carter, CA; Fanger, GR; Fitch, WL; Infante, JR; Kim, MM; Knox, SJ; Korn, R; Lao, CD; Ning, S; Oronsky, A; Oronsky, B; Peehl, DM; Reid, T; Scicinski, J; Scribner, CL; Stirn, M; Taylor, MJ, 2015)	2.17
" RRx-001 is a minimally toxic small molecule with a distinct chemical structure and mechanism of action."	( Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development. Abrouk, N; Cabrales, P; Cannizzo, L; Caroen, S; Guo, X; Lybeck, M; Oronsky, A; Oronsky, B; Reid, TR; Sher, D; Wang, X; Wardle, B, 2021)	1.9
" There were no severe adverse events attributed to the study drug."	( PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy. Abrouk, N; Bar-Ad, V; Biagioli, M; Blakaj, DM; Bonomi, M; Caroen, S; Colvett, K; Goyal, S; Kabarriti, R; Muzyka, B; Niermann, K; Oronsky, B; Reid, T; Sher, DJ; Sonis, S; Takiar, V, 2023)	1.14

Dosage Studied

Excerpt	Relevance	Reference
" U87 tumors showed an absence of blood flow over large areas of treated tumors after dosing with RRx-001."	( RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Cabrales, P; Minchinton, A; Oronsky, B; Scicinski, J, 2016)	2.09

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (80)

Assay ID	Title	Year	Journal	Article
AID1220447	Binding affinity to monkey hemoglobin assessed as protein bound compound level at 20 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220450	Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-(hydroxyimino)azetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of excess reduced GSH at pH 7.8 by LC-MS/MS meth	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220395	Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220431	Drug excretion in Wistar Hanover rat urine at 10 mg/kg, iv administered as single dose after 0 to 8 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220400	Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220404	Drug metabolism in rat whole blood assessed as [(R)-2-(2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanamido)acetic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814607	Antiproliferative activity against human IMR-32 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220419	Binding affinity to dog hemoglobin assessed as protein bound compound level at 20 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220435	Drug level in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose after 168 hrs relative to total radioactivity	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220433	Ratio of drug level in blood to plasma in Wistar Hanover rat at 10 mg/kg, iv administered as single dose after 0.083 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220392	Retention time in rat whole blood in presence of 0.1% formic acid in water at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220390	Retention time in human whole blood at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220401	Drug metabolism in human whole blood assessed as [(R)-2-amino-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220448	Binding affinity to human hemoglobin assessed as protein bound compound level at 20 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220430	Drug excretion in Wistar Hanover rat urine at 10 mg/kg, iv administered as single dose after 168 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220449	Retention time in rat whole blood at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220420	Ratio of drug level in dog blood to dog plasma at 20 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814599	Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220391	Retention time in human whole blood in presence of 0.1% formic acid in water at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220437	Drug level in Wistar Hanover rat stomach at 10 mg/kg, iv administered as single dose after 24 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220399	Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220425	AUC (0 to t) in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220427	Volume of distribution in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220406	Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-1-oxo-3-((2-oxo-2-(3-oxoazetidin-1-yl)ethyl)thio)propan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220414	Binding affinity to rat hemoglobin assessed as protein bound compound level at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220412	Ratio of drug level in monkey blood to monkey plasma at 20 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1882259	Cytotoxicity against human multiple myeloma cells by WST-1 assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1220440	Stability in water	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814595	Antitumor activity against mouse SCC-7 cells implanted in C3H mouse assessed as tumor growth time at 12 mg/kg, ip treated every other day 3 times in total (Rvb = 2.8 +/- 0.6 day)	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220429	Drug excretion in Wistar Hanover rat feces at 10 mg/kg, iv administered as single dose measured on day 1	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220421	Half life in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220451	Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-1-oxo-3-((2-oxo-2-(3-oxoazetidin-1-yl)ethyl)thio)propan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of excess reduced GSH at pH 7.8 by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220403	Drug metabolism in human whole blood assessed as [(R)-2-(2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanamido)acetic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220405	Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-1-oxo-3-((2-oxo-2-(3-oxoazetidin-1-yl)ethyl)thio)propan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814597	Antiproliferative activity against mouse SCC-7 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220434	Drug excretion in Wistar Hanover rat feces at 10 mg/kg, iv administered as single dose measured on day 7	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814603	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220424	Volume of distribution in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814602	Antiproliferative activity against human RKO cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220416	Binding affinity to monkey hemoglobin assessed as protein bound compound level at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220452	Ratio of drug level in rat blood to rat plasma at 1 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220418	Binding affinity to rat hemoglobin assessed as protein bound compound level at 20 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220417	Binding affinity to human hemoglobin assessed as protein bound compound level at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220453	Ratio of drug level in dog blood to dog plasma at 1 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220397	Drug metabolism in human whole blood assessed as (R)-2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814604	Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220442	Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of reduced GSH at pH 7.8 by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220394	Retention time in rat whole blood in presence of 0.1% formic acid in acetonitrile at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220438	Drug level in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose after 24 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814605	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220441	Stability in pH 7.0 buffer	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814601	Antiproliferative activity against human U87 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220398	Drug metabolism in rat whole blood assessed as (R)-2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220393	Retention time in human whole blood in presence of 0.1% formic acid in acetonitrile at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220407	Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-(hydroxyimino)azetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220415	Binding affinity to dog hemoglobin assessed as protein bound compound level at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220411	Binding affinity to human hemoglobin assessed as alkylation on Hb beta chain Cys-93 locus at 0.53 to 5.5 mM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220413	Ratio of drug level in human blood to human plasma at 20 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220439	Drug level in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose after 168 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814600	Antiproliferative activity against human M21 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1814598	Antiproliferative activity against human UMSCC22B cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1814608	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220422	AUC (0 to t) in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220408	Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-(hydroxyimino)azetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220402	Drug metabolism in rat whole blood assessed as [(R)-2-amino-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220456	Ratio of drug level in rat blood to rat plasma at 20 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220428	Drug excretion in Wistar Hanover rat feces at 10 mg/kg, iv administered as single dose measured on day 2	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220454	Ratio of drug level in monkey blood to monkey plasma at 1 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220432	Ratio of drug level in blood to plasma in Wistar Hanover rat at 10 mg/kg, iv administered as single dose after 168 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814596	Antitumor activity against mouse SCC-7 cells implanted in C3H mouse assessed as tumor growth time delay at 12 mg/kg, ip treated every other day 3 times in total	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220396	Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814606	Antiproliferative activity against human A498 cells assessed as cell growth inhibition by CCK8 assay	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220455	Ratio of drug level in human blood to human plasma at 1 uM after 30 mins	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814609	Terminal half life in human plasma	2021	Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220426	AUC (0 to infinity) in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220436	Drug level in Wistar Hanover rat bile at 10 mg/kg, iv administered as single dose after 24 hrs	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220445	Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of excess reduced GSH at pH 7.8 by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220423	Half life in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220444	Drug metabolism assessed as (R)-2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation after 1 hr in presence of cysteine at pH 7.8 by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9	Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	31 (68.89)	24.3611
2020's	14 (31.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	33.85 (24.57)
Research Supply Index	3.93 (2.92)
Research Growth Index	4.61 (4.65)
Search Engine Demand Index	43.69 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (33.85)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (11.11%)	5.53%
Reviews	9 (20.00%)	6.00%
Case Studies	3 (6.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	28 (62.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.21	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	3.23	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	3.23	1	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
entinostat [no description available]	4.13	2	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.19	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide [no description available]	7.31	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.71	2	0	phthalimides; piperidones
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.21	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	4.42	3	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.13	1	0	C-nitro compound; imidazoles	antitubercular agent
nitroxoline nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.	3.51	1	0	C-nitro compound; monohydroxyquinoline	antifungal agent; antiinfective agent; antimicrobial agent; renal agent
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	3.5	1	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
etoposide [no description available]	9.87	2	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.21	1	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
pimonidazole pimonidazole: structure given in first source	2.13	1	0
irinotecan [no description available]	8.97	2	1	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.51	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.11	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	2.25	1	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
pomalidomide 3-aminophthalimidoglutarimide: structure in first source	3.71	2	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
lenalidomide [no description available]	3.51	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
bortezomib [no description available]	3.71	2	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
gant 61 GANT 61: a sonic hedgehog pathway inhibitor and Gli inhibitor; structure in first source. GANT61 : An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor.	3.51	1	0	aminal; dialkylarylamine; pyridines; substituted aniline; tertiary amino compound	antineoplastic agent; apoptosis inducer; glioma-associated oncogene inhibitor; Hedgehog signaling pathway inhibitor
carboplatin [no description available]	4.9	2	1
decitabine [no description available]	3.19	1	0	2'-deoxyribonucleoside
nadp [no description available]	2.13	1	0
p5091 P5091: inhibits ubiquitin-specific protease 7; structure in first source	3.78	2	0
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.54	2	0	cysteinium	fundamental metabolite
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	3.51	1	0	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
regorafenib [no description available]	3.5	1	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
epoxomicin [no description available]	3.51	1	0	morpholines; tripeptide	proteasome inhibitor
carfilzomib [no description available]	3.51	1	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	3.51	1	0	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
sodium nitrite Sodium Nitrite: Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.. sodium nitrite : An inorganic sodium salt having nitrite as the counterion. Used as a food preservative and antidote to cyanide poisoning.	2.15	1	0	inorganic sodium salt; nitrite salt	antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	3.51	1	0	piperazines
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	3.51	1	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
arry 520 filanesib: a kinesin spindle protein inhibitor	3.51	1	0
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	3.51	1	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
acy-1215 ricolinostat: an HDAC6 inhibitor; structure in first source	3.51	1	0	pyrimidinecarboxylic acid
selinexor selinexor: inhibits karyopherin XPO1	3.51	1	0
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.17	1	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	0	9.47	16	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	9.47	16	2
Kahler Disease [description not available]	0	3.53	2	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	8.53	2	0
Innate Inflammatory Response [description not available]	0	4.02	3	0
Periphlebitis Periphlebitis is inflammation of the outer coat of a vein or of tissues surrounding the vein.	0	2.41	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	4.02	3	0
Phlebitis Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).	0	2.41	1	0
Cancer of Head [description not available]	0	4.91	1	1
Mucositis, Oral [description not available]	0	4.91	1	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	4.91	1	1
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	1	6.91	1	1
Cancer, Second Primary [description not available]	0	3.99	1	1
Cancer of Lung [description not available]	0	6.32	4	1
Lung Neoplasms Tumors or cancer of the LUNG.	0	6.32	4	1
Carcinoma, Small Cell Lung [description not available]	0	4.51	1	1
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	0	4.51	1	1
2019 Novel Coronavirus Disease [description not available]	0	2.25	1	0
Thrombopenia [description not available]	0	2.31	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	7.31	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	7.31	1	0
Allergic Encephalomyelitis [description not available]	0	2.31	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	0	2.31	1	0
Benign Neoplasms, Brain [description not available]	0	2.59	2	0
Glial Cell Tumors [description not available]	0	2.31	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	1	4.59	2	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	7.31	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.82	3	0
Injury, Ischemia-Reperfusion [description not available]	0	2.15	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	7.15	1	0
Androgen-Independent Prostatic Cancer [description not available]	0	2.17	1	0
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	0	2.17	1	0
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	0	2.17	1	0
Hypercoagulability [description not available]	0	2.17	1	0
Thrombophilia A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.	0	2.17	1	0
Bladder Cancer [description not available]	0	2.21	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	0	2.21	1	0
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	0	2.11	1	0
Cerebral Malaria [description not available]	0	7.11	1	0
Anoxemia [description not available]	0	3.44	2	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	8.44	2	0
Adverse Drug Event [description not available]	0	4.41	1	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	4.41	1	1
Carcinoma, Epidermoid [description not available]	0	2.49	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.49	2	0
Malignant Melanoma [description not available]	0	2.13	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	7.13	1	0
Disease Exacerbation [description not available]	0	3.04	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	3.45	2	0
Local Neoplasm Recurrence [description not available]	0	3.04	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	3.45	2	0
Experimental Neoplasms [description not available]	0	2.13	1	0
Cancer of Colon [description not available]	0	2.15	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.15	1	0
Metastase [description not available]	0	3.5	1	1
Colorectal Cancer [description not available]	0	3.5	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	3.5	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1	5.5	1	1

chemdatabank.com